LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Search

Charles River Laboratories International Inc

Closed

SectorHealthcare

151.8 -2.4

Overview

Share price change

24h

Current

Min

151.57

Max

158.21

Key metrics

By Trading Economics

Income

-332M

-277M

Sales

-11M

994M

EPS

2.43

Profit margin

-27.816

Employees

18,300

EBITDA

730K

198M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+32.44% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2026

Market Stats

By TradingEconomics

Market Cap

772M

8.7B

Previous open

154.2

Previous close

151.8

News Sentiment

By Acuity

10%

90%

9 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 mar 2026, 21:37 UTC

Acquisitions, Mergers, Takeovers

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Major News Events

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Market Talk

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Market Talk

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Market Talk
Major News Events

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Acquisitions, Mergers, Takeovers

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk
Major News Events

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Major News Events

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Market Talk

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Market Talk

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Market Talk
Major News Events

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Major News Events

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Market Talk
Major News Events

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Market Talk

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Market Talk

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Major News Events

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Market Talk

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Major News Events

Trump Ends News Conference

Peer Comparison

Price change

Charles River Laboratories International Inc Forecast

Price Target

By TipRanks

32.44% upside

12 Months Forecast

Average 205.89 USD  32.44%

High 265 USD

Low 175 USD

Based on 11 Wall Street analysts offering 12 month price targets forCharles River Laboratories International Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

117.16 / 144.77Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

9 / 351 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat